leisure time -WSS

leisure time

author：Wikipedia 2025-10-01 14:19:50 - browse：485

IQVIA signage. -- health tech coverage from STAT — Adobe

The health data giant IQVIA became a dominant force by gobbling up its rivals. Over decades, it feasted on upstarts with new datasets or novel technologies, growing into a juggernaut with no peer in the business of brokering Americans’ medical information.

Now, government regulators say, IQVIA’s appetite for acquisition is getting out of control — and must be reined in.

A Federal Trade Commission lawsuit seeking to block its acquisition of the digital advertising firm DeepIntent marks a crossroads for the company and the multi-billion dollar medical advertising economy it serves. The agency, which is seeking an injunction and temporary restraining order in federal court, argues that IQVIA’s data vault has become so large — and revealing — that it forms the substrate of an entire industry focused on showering doctors and patients with marketing messages.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Readout Newsletter: CAR

WSS

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

ER docs worry over extreme heat as a 'mass casualty event'

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Wikipedia

leisure time

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

WuXi out of biotech trade group, U.S. and China relations to blame

Drug repurposing or repositioning? The language matters

ER docs worry over extreme heat as a 'mass casualty event'

Hepatitis C has a cure — but many Americans still lack access to it

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

How to save PrEP access — and even expand it

Ebola: Gilead Sciences antiviral shows promise as new treatment

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

knowledge

BridgeBio heart drug succeeds in pivotal study

WuXi out of biotech trade group, U.S. and China relations to blame

John Green on his newest strategy for fighting tuberculosis

UK homeowners get some respite as inflation falls by more than anticipated to a 15

Robert Kennedy Jr.'s presidential campaign attracts GOP

BridgeBio heart drug succeeds in pivotal study

explore

Wikipedia

leisure time

leisure time